Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism

Drug Metabolism Reviews

Volumn 35, Issue 1, 2003, Pages 1-18

  Lewis, David F V ^a   Dickins, Maruice ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cytochromes P450; Human drug metabolism; Lipophilicity

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; 4 NITROANISOLE; 7 ETHOXYCOUMARIN; AMFEBUTAMONE; AMINO ACID; BENZPHETAMINE; CAFFEINE; COTININE; COUMARIN ANTICOAGULANT; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2A; CYTOCHROME P450 3A; DIAZEPAM; DRUG METABOLIZING ENZYME; ETHOXYRESORUFIN; LOSIGAMONE; MELATONIN; MEPHENYTOIN; NICOTINE; OCTANOL; PARACETAMOL; PHENACETIN; PHENAZONE; RESORUFIN DERIVATIVE; TERFENADINE; TESTOSTERONE; TOLBUTAMIDE; UNINDEXED DRUG; WATER;

AMINO ACID ANALYSIS; ARTICLE; BINDING KINETICS; DISEASE ASSOCIATION; DRUG METABOLISM; ENERGY; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME BINDING; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIPOPHILICITY; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MICHAELIS CONSTANT; MOLECULAR STABILITY; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PROTEIN FAMILY; PROTEIN INTERACTION;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIPID METABOLISM; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 0037281964     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120018245     Document Type: Article

References (35)

1. Anzenbacher, P., Anzenbacherova, E. (2001). Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 58:737-747.
2. m and the relevant ΔG° values - possible implications in chemotherapy and biotechnology. Biochem. Pharmacol. 61:1049-1055.
3. Creighton, T.E. (1993). Proteins: Structure and Molecular Properties, Freeman, New York.
4. Ekins, S., Wrighton, S. A. (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31:719-754.
5. Ekins, S., Bravi, G., Wikel, J. H., Wrighton, S. A. (1999). Three-dimensional quantitative structure-activity relationship analysis of cytochrome P4503A4 substrates. J. Pharmacol. Exp. Ther. 291:424-433.
6. Ferrari, S., Leeman, T., Dayer, P. (1991). The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro. Life Sci. 48:2259-2265.
7. m. Drug Metab. Rev. 28:513-526.
8. Hansch, C., Leo, A. (1979). Substituent Constants for Correlation Analysis in Chemistry and Biology. New York: Wiley.
9. Hansch, C., Zhang, L. (1993). Quantitative structure-activity relationships of cytochrome P450. Drug Metab. Rev. 25:1-48.
10. Hosea, N. A., Miller, G. P., Guengerich, F. P. (2000). Elucidation of distinct ligand binding sites for cytochrome P4503A4. Biochemistry 39:5929-5939.
11. Kenworthy, K. E., Bloomer, J. C., Clarke, S. E., Houston, J. B. (1999). CYP3A4 drug interactions: correlations of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48:716-727.
12. Lewis, D. F. V. (1996). Cytochromes P450: Structure, Function and Mechanism. London: Taylor & Francis.
13. Lewis, D. F. V. (2000a). On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem. Pharmacol. 60:293-306.
14. Lewis, D. F. V. (2000b). Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 144:197-203.
15. Lewis, D. F. V. (2000c). Modelling human cytochromes P450 for evaluating drug metabolism: an update. Drug Metab. Drug Interactions 16:307-324.
16. Lewis, D. F. V. (2001). Guide to Cytochromes P450 Structure and Function. London: Taylor & Francis.
17. Lewis, D. F. V. (2002a). Molecular modeling of human cytochrome P450-substrate interactions. Drug Metab. Rev. 34:55-67.
18. Lewis, D. F. V. (2002b). Homology modelling of human CYP2 family enzymes based on the CYP2C5 structure. Xenobiotica 32:305-323.
19. Lewis, D. F. V., Broughton, H. B. (2002). Molecular binding interactions: their estimation and rationalization in QSARs in terms of theoretically derived parameters. Sci. World 2:1776-1802.
20. Lewis, D. F. V., Dickins, M. (2002a). Factors influencing rates and clearance in P450mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. Toxicology 170:45-53.
21. Lewis, D. F. V., Dickins, M. (2002b). Substrate SARs in human P450s. Drug Discov. Today, in press.
22. Lewis, D. F. V., Eddershaw, P. J., Dickins, M., Tarbit, M. H., Goldfarb, P. S. (1998). Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chem. Biol. Interact. 115:175-199.
23. Lewis, D. F. V., Modi, S., Dickins, M. (2001). Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metab. Drug Interact. 18:221-241.
24. Lewis, D. F. V., Modi, S., Dickins, M. (2002). Structure-activity relationships for human cytochrome P450 substrates and inhibitors. Drug Metab. Rev. 34:69-82.
25. Lipnick, R. L., Johnson, D. E., Gilford, J. H., Bickings, C. K., Newsome, L. D. (1985). Comparison of fish toxicity screening data for 55 alcohols with the quantitative structure-activity relationship predictions of minimum toxicity for nonreactive nonelectrolyte organic compounds. Environ. Toxicol. Chem. 4:281-296.
26. Mancy, A., Broto, P., Dijols, S., Dansette, P. M., Mansuy, D. (1995). The substrate binding site of human liver cytochrome P4502C9: an approach using tienilic acid derivatives and molecular modelling. Biochemistry 34:10365-10375.
27. Miyazawa, M., Shindo, M., Shimada, T. (2001). Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes. Xenobiotica 31:713-723.
28. Ortiz de Montellano, P. R. (1995). Cytochrome P450. 2nd ed. New York: Plenum.
29. Pelkonen, O., Maenpaa, J., Taavitsainen, P., Rautio, A., Raunio, H. (1998). Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
30. Rendic, S. (2002). Summary of information on human CYP enzymes: human CYP metabolism data. Drug Metab. Rev. 34:83-448.
31. Rendic, S., DiCarlo, F. J. (1997). Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. 29:413-580.
32. Sangster, J. (1989). Octanol-water partition coefficients of simple organic compounds. J. Phys. Chem. Ref. Data 18:1111-1229.
33. Smith, D. A., Jones, B. C. (1992). Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 44:2089-2098.
34. Suzuki, T., Kudo, Y. (1990). Automatic log P estimation based on combined additive modeling methods. J. Comput.-Aided Mol. Des. 4:155-198.
35. Ueng, Y. -F., Kuwabara, T., Chun, Y. -J., Guengerich, F. P. (1997). Cooperativity in oxidations catalyzed by cytochrome P4503A4. Biochemistry 36:370-381.